Targeting key immune checkpoints, such as programmed death-1 (PD-1) or its ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), with antibodies is now a recognized treatment option for several cancers [1]. This evidence concerns the gene CD274 and cancer.